The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis

Overview

Peritoneal dialysis (PD) is a widely used modality of renal replacement therapy. Due to its continuous nature of therapy, better control of fluid status and preservation of residual renal function were presumed by most nephrologists. However, recent evidences showed that it might not be the case. The severity of fluid overloading and the need for anti-hypertensive agents to control blood pressure seems to be more severe for PD patients. Therefore, more aggressive strategy to control dry weight is mandatory in PD patients. However, over reduction of dry weight might affect residual renal function (RRF) and, probably, the survival of PD patients. A balance between reduction of dry weight and preservation of RRF is crucial for the care of PD patients. Currently, only clinical measures like cardiothoracic ratio on chest X-ray and absence of pedal edema were used to evaluate PD patient's dry weight. There is no objective method to determine dry weight accurately. In this prospective and randomized study, the investigators will use multi-frequency bio-impedance (MF-BIA) to detect intracellular and extracellular water (ECW) content of patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2007

Interventions

  • Device: Bioelectrical impedance-guide dry weight reduction
    • for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration

Arms, Groups and Cohorts

  • Experimental: Monthly BIA
    • monthly BIA to monitor fluid status

Clinical Trial Outcome Measures

Primary Measures

  • systolic blood pressure
    • Time Frame: one year

Participating in This Clinical Trial

Inclusion Criteria

  • age 18 to 80 Exclusion Criteria:

  • type I DM – Severe heart failure – unstable angina

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Taipei Veterans General Hospital, Taiwan
  • Provider of Information About this Clinical Study
    • Jinn-Yang Chen, Taipei Veterans General Hospital
  • Overall Official(s)
    • Jinn-Yang Chen, MD, PhD, Principal Investigator, Division of Nephrology, Taipei Veterans General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.